Medite Cancer Diagnostics Inc
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controll… Read more
Medite Cancer Diagnostics Inc (MDIT) - Net Assets
Latest net assets as of September 2018: $6.44 Million USD
Based on the latest financial reports, Medite Cancer Diagnostics Inc (MDIT) has net assets worth $6.44 Million USD as of September 2018.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.65 Million) and total liabilities ($11.21 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.44 Million |
| % of Total Assets | 36.47% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.98 |
Medite Cancer Diagnostics Inc - Net Assets Trend (2013–2017)
This chart illustrates how Medite Cancer Diagnostics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medite Cancer Diagnostics Inc (2013–2017)
The table below shows the annual net assets of Medite Cancer Diagnostics Inc from 2013 to 2017.
| Year | Net Assets | Change |
|---|---|---|
| 2017-12-31 | $5.78 Million | -27.79% |
| 2016-12-31 | $8.00 Million | -12.74% |
| 2015-12-31 | $9.17 Million | +8.72% |
| 2014-12-31 | $8.43 Million | +297.35% |
| 2013-12-31 | $-4.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medite Cancer Diagnostics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 450.7% over the analyzed period, potentially due to dividend distributions or operating losses.
- The company has 5.7% of equity in treasury stock, representing shares repurchased from the open market.
Current Equity Component Breakdown (December 2017)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $29.00K | 0.50% |
| Treasury Stock | $327.00K | 5.66% |
| Other Comprehensive Income | $-444.00K | -7.69% |
| Other Components | $14.71 Million | 254.75% |
| Total Equity | $5.78 Million | 100.00% |
Medite Cancer Diagnostics Inc Competitors by Market Cap
The table below lists competitors of Medite Cancer Diagnostics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ZHUGUANG HOLDINGS
BE:NA7
|
$1.73K |
|
PT Timah Tbk
MU:TIH1
|
$1.73K |
|
QUESTERRE ENERGY-A
MU:QE1
|
$1.73K |
|
SPANISH MTN GLD
MU:S3Y
|
$1.74K |
|
MYDECINE INNOVAT.GRP
F:0NF0
|
$1.73K |
|
Thanh Nam Group JSC
VN:TNI
|
$1.73K |
|
Alchemy Investments Acquisition Corp 1 Warrants
NASDAQ:ALCYW
|
$1.73K |
|
SPC Power Corp
PSE:SPC
|
$1.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medite Cancer Diagnostics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2016 to 2017, total equity changed from 7,998,000 to 5,775,000, a change of -2,223,000 (-27.8%).
- Net loss of 6,811,000 reduced equity.
- Share repurchases of 2,531,000 reduced equity.
- Other comprehensive income increased equity by 198,000.
- Other factors increased equity by 6,921,000.
Equity Change Factors (2016 to 2017)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.81 Million | -117.94% |
| Share Repurchases | $2.53 Million | -43.83% |
| Other Comprehensive Income | $198.00K | +3.43% |
| Other Changes | $6.92 Million | +119.84% |
| Total Change | $- | -27.79% |
Book Value vs Market Value Analysis
This analysis compares Medite Cancer Diagnostics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $0.45 | $0.00 | x |
| 2016-12-31 | $0.37 | $0.00 | x |
| 2017-12-31 | $0.22 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medite Cancer Diagnostics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -117.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.97%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 2.76x
- Recent ROE (-117.94%) is below the historical average (-32.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 2.06% | 225.00% | 1.14x | 0.01x | $-208.40K |
| 2014 | -10.07% | -6.36% | 0.59x | 2.68x | $-1.39 Million |
| 2015 | -9.37% | -8.69% | 0.54x | 2.01x | $-1.78 Million |
| 2016 | -27.04% | -23.41% | 0.53x | 2.19x | $-2.96 Million |
| 2017 | -117.94% | -99.97% | 0.43x | 2.76x | $-7.39 Million |
Industry Comparison
This section compares Medite Cancer Diagnostics Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medite Cancer Diagnostics Inc (MDIT) | $6.44 Million | 2.06% | 1.74x | $1.73K |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |